TransCode Therapeutics宣布 1换 28的反向股票分割-动脉网

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

CISION 等信源发布 2025-05-03 04:10



可切换为仅中文







Split designed to achieve compliance with Nasdaq minimum bid price requirements

拆分旨在实现符合纳斯达克最低出价要求

BOSTON

波士顿

，

May 2, 2025

2025年5月2日

/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq:

/PRNewswire/ -- TransCode Therapeutics, Inc.（纳斯达克：

RNAZ

) ('TransCode' or the 'Company'), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on

）（“TransCode”或“公司”），即致力于通过RNA疗法更有效治疗癌症的RNA肿瘤学公司™，今天宣布其董事会已批准1比28的反向股票分割。该反向股票分割已由TransCode的股东于

May 2, 2025

2025年5月2日

, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

，并旨在提高公司普通股的每股交易价格，以使公司能够满足纳斯达克资本市场持续上市的最低出价要求。

The 1-for-28 reverse stock split will automatically convert twenty-eight current shares of TransCode's common stock into one new share of common stock. No fractional shares will be issued in connection with the reverse stock split. In lieu of issuing fractional shares, stockholders of record who otherwise would be entitled to receive fractional shares will be entitled to rounding up of the fractional share to the nearest whole number.

1比28的反向股票分割将自动把二十八股TransCode现有普通股转换为一股新的普通股。反向股票分割不会发行零碎股。作为发行零碎股的替代方案，原本有权获得零碎股的记录在册的股东将有权将其零碎股向上舍入为最接近的整数股。

The reverse split will reduce the number of shares of common stock outstanding from 23,341,336 shares to approximately 833,620 shares. Proportional adjustments also will be made to the exercise prices of TransCode's outstanding stock options and warrants, and to the number of shares issued and issuable under TransCode's stock incentive plans..

反向分割将使流通股数量从 23,341,336 股减少到约 833,620 股。TransCode 未偿还的股票期权和认股权证的行权价格，以及根据 TransCode 的股票激励计划已发行和可发行的股份数量也将进行相应调整。

Vstock Transfer LLC will act as the exchange agent for the reverse stock split. Stockholders of record are not required to take any action to receive post-split shares in book-entry. Stockholders owning shares through a bank, broker, custodian or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to the holding entity's particular processes; such stockholders will not be required to take any action in connection with the reverse stock split.

Vstock Transfer LLC将作为反向股票分割的交换代理。记录在案的股东无需采取任何行动即可接收分割后的股份电子记录。通过银行、经纪人、托管人或其他名义持有人持有股份的股东，其持仓将自动调整以反映反向股票分割，具体调整受相关持有实体的具体流程影响；这些股东无需就反向股票分割采取任何行动。

However, these banks, brokers, custodians or other nominees may have different procedures for processing the reverse stock split than those for registered stockholders. If a stockholder holds shares of common stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee for more information..

然而，这些银行、经纪商、托管人或其他名义持有人处理反向股票分割的程序可能与注册股东的程序不同。如果股东持有由银行、经纪商、托管人或其他名义持有人保管的普通股，并对此有任何疑问，建议股东联系其银行、经纪商、托管人或其他名义持有人以获取更多信息。

The effective date of the reverse stock split has not yet been determined and will be announced by the Company at least two business days prior to its implementation.

反向股票分割的生效日期尚未确定，公司将在实施前至少两个工作日宣布。

About TransCode Therapeutics

关于TransCode治疗学

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.

TransCode是一家临床阶段的肿瘤学公司，专注于治疗转移性疾病。公司致力于通过其专有的TTX纳米粒子平台，智能设计和有效递送RNA疗法来战胜癌症。公司的主要治疗候选药物TTX-MC138专注于治疗过表达microRNA-10b的转移性肿瘤，microRNA-10b是一种独特且有充分文献记录的转移生物标志物。

In addition, TransCode is developing a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers. .

此外，TransCode 正在开发一系列其他首创 RNA 治疗候选药物，旨在克服 RNA 递送的挑战，从而解锁对多种新型基因靶点的治疗访问，这些靶点可能与治疗多种癌症相关。

Forward-Looking Statements

前瞻性声明

This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words.

本新闻稿包含“前瞻性陈述”，这些陈述受到重大风险和不确定性的影响。本新闻稿中除历史事实陈述之外的所有陈述均为前瞻性陈述。本新闻稿中的前瞻性陈述可以通过使用诸如“预期”、“相信”、“考虑”、“可能”、“估计”、“预计”、“意图”、“寻求”、“或许”、“也许”、“计划”、“潜在”、“预测”、“预计”、“目标”、“瞄准”、“应该”、“将”、“会”等词语或这些词语的否定形式或其他类似表达来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including the Company's expectations regarding the effect of the reverse stock split and its continued listing on Nasdaq.

前瞻性声明基于公司当前的预期，并受制于难以预测的内在不确定性、风险和假设。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能被证明不准确，包括公司对反向股票分割的影响及其在纳斯达克继续上市的预期。

These and other risks and uncertainties are described more fully in the sections titled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in the Company's Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law..

这些以及其他风险和不确定性在公司年度报告表格10-K中标题为“风险因素”和“关于前瞻性陈述的警示说明”的章节中有更详细的描述，该报告已提交给证券交易委员会。本公告中包含的前瞻性陈述是截至本日期作出的，公司不承担更新此类信息的义务，除非适用法律要求。

SOURCE TransCode Therapeutics, Inc.

源代码：TransCode Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers